McGuire W Cameron, Sullivan Lauren, Odish Mazen F, Desai Brinda, Morris Timothy A, Fernandes Timothy M
Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California, San Diego, La Jolla, CA.
Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California, San Diego, La Jolla, CA.
Chest. 2024 Dec;166(6):1532-1545. doi: 10.1016/j.chest.2024.04.032. Epub 2024 Jun 1.
Acute pulmonary embolism (PE) is a common disease encountered by pulmonologists, cardiologists, and critical care physicians throughout the world. For patients with high-risk acute PE (defined by systemic hypotension) and intermediate high-risk acute PE (defined by the absence of systemic hypotension, but the presence of numerous other concerning clinical and imaging features), intensive care often is necessary. Initial management strategies should focus on optimization of right ventricle (RV) function while decisions about advanced interventions are being considered.
We reviewed the existing literature of various vasoactive agents, IV fluids and diuretics, and pulmonary vasodilators in both animal models and human trials of acute PE. We also reviewed the potential complications of endotracheal intubation and positive pressure ventilation in acute PE. Finally, we reviewed the data of venoarterial extracorporeal membrane oxygenation use in acute PE. The above interventions are discussed in the context of the underlying pathophysiologic features of acute RV failure in acute PE with corresponding illustrations.
Norepinephrine is a reasonable first choice for hemodynamic support with vasopressin as an adjunct. IV loop diuretics may be useful if evidence of RV dysfunction or volume overload is present. Fluids should be given only if concern exists for hypovolemia and absence of RV dilatation. Supplemental oxygen administration should be considered even without hypoxemia. Positive pressure ventilation should be avoided if possible. Venoarterial extracorporeal membrane oxygenation cannulation should be implemented early if ongoing deterioration occurs despite these interventions.
急性肺栓塞(PE)是全球肺科医生、心脏病专家和重症医学医生常见的疾病。对于高危急性PE患者(定义为全身性低血压)和中高危急性PE患者(定义为无全身性低血压,但存在许多其他相关临床和影像学特征),通常需要重症监护。初始管理策略应侧重于优化右心室(RV)功能,同时考虑高级干预措施的决策。
我们回顾了各种血管活性药物、静脉输液和利尿剂以及肺血管扩张剂在急性PE动物模型和人体试验中的现有文献。我们还回顾了急性PE中气管插管和正压通气的潜在并发症。最后,我们回顾了急性PE中静脉-动脉体外膜肺氧合使用的数据。上述干预措施在急性PE急性RV衰竭的潜在病理生理特征背景下进行了讨论,并配有相应插图。
去甲肾上腺素是血流动力学支持的合理首选,血管加压素作为辅助药物。如果存在RV功能障碍或容量超负荷的证据,静脉注射袢利尿剂可能有用。仅在存在血容量不足且无RV扩张的情况下才应给予液体。即使没有低氧血症,也应考虑补充氧气。应尽可能避免正压通气。如果尽管采取了这些干预措施仍持续恶化,则应尽早实施静脉-动脉体外膜肺氧合插管。